Financial Performance - The company achieved operating revenue of ¥186,558,411.61, representing a year-on-year increase of 6.68%[6] - Net profit attributable to shareholders decreased by 49.75% to ¥5,899,486.86 compared to the previous year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 67.03% to ¥3,673,231.34[6] - The basic earnings per share dropped by 62.50% to ¥0.06[4] Assets and Equity - Total assets at the end of the reporting period were ¥472,767,891.99, reflecting a year-on-year growth of 12.74%[6] - Shareholders' equity attributable to the company decreased by 1.69% to ¥355,621,742.02[6] Expenses and Costs - Sales expenses increased by 57.32% to ¥45,783,494.31, significantly impacting net profit[7] - Increased promotional expenses due to the expansion of overseas subsidiaries contributed to the rise in sales costs[7] - The company experienced higher platform and sales costs due to increased sales revenue from Amazon[7] Cautionary Notes - The financial data presented is preliminary and has not been audited, cautioning investors about potential risks[8]
锦好医疗(872925) - 2024 Q4 - 年度业绩